<DOC>
	<DOCNO>NCT00619528</DOCNO>
	<brief_summary>The purpose study attempt eliminate necessity immunosuppressive therapy HLA-identical sibling Kidney Transplants , examine cellular chimerism donor hematopoietic stem cell ( DHSC ) lineages pairs demonstrate immunologic unresponsiveness , investigate safety efficacy treatment regimen include withdrawal immunosuppression one year post-transplant recipient receive DHSC infusion .</brief_summary>
	<brief_title>HLA-Identical Sibling Renal Transplant Tolerance</brief_title>
	<detailed_description>Primary Study Objectives : 1 . To remove immunosuppressive therapy recipient HLA-identical sibling renal transplant within 24 month transplantation . 2 . To detect follow cellular ( macro ) chimerism donor hematopoietic stem cell ( DHSC ) lineages generation T-regulatory cell use specialized immunomonitoring assay donor/recipient pair demonstrate specific immunologic unresponsiveness . 3 . To investigate safety efficacy treatment regimen consist induction therapy Campath-1H steroid-free low dose maintenance immunosuppression , consist mycophenolate mofetil ( MMF ) tacrolimus convert sirolimus . This follow complete withdrawal immunosuppression begin one year , minimum , post transplant , recipient also give four infusion purify donor hematopoietic Cluster Differentiation ( CD ) 34+ stem cell ( DHSC ) .</detailed_description>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patient fully inform , sign date Institutional Review Board ( IRB ) approve informed consent form obtain directly P.I. , CoP.I. , Res . Nurse , willing follow study procedure duration study ( 3 yr ) . Recipient : hematocrit ≥ 33 % , hemoglobin ≥ 11.0 g/dL . Weight &gt; 40 kg . Primary renal allograft : living relate ( HLAidentical donorrecipient sibling pair ) Negative Bcell Tcell cytotoxic crossmatch , low ( ≤ 10 % ) Panel Reactive Antibody ( PRA ) use cytotoxicity . Women childbearing potential : negative qualitative serum pregnancy test . Patients study equivalently available transplant use criterion , w/out regard gender , race , ethnicity . Normal echocardiogram w/ ejection fraction &gt; 50 % . Male participant w/ reproductive potential agree use approve method birth control treatment w/ Campath1H minimum 6 month follow last dose . Female participant childbearing potential agree use approve method birth control duration participation study . Patient agree followup every 2 month year 3 , 10 year . Patient previously received/receiving transplant kidney . Patient receive ABO ( blood type ) incompatible donor kidney . Recipient/donor ELISA positive human immunodeficiency virus ( HIV ) , antibody positive hep . C , surface antigen positive hep . B . Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squa¬mous cell carcinoma skin , carcinoma situ cervix treat successfully . Patients w/ significant liver disease , define past 28 day continuously elevated aspartate aminotransferase ( AST ( SGOT ) ) and/or Alanine Aminotransferase ( ALT ( SGPT ) ) level great 3 time upper value normal range center . Patient uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer unstable medical condition could interfere w/ study objective . Patient currently receive investigational drug receive investigational drug within 30 day pretransplant . Patient currently receive immunosuppressive agent . In investigator 's judgment , anticipated patient unable take medication orally via nasogastric tube morning second day ( i.e. , skin closure ) . Concurrent use warfarin , fluvastatin , astemizole , pimozide , cisapride , terfenadine , ketoconazole . Patient hypersensitivity tacrolimus , Campath1H , Thymoglobulin , daclizumab ( Zenapax® ) , sirolimus , MMF corticosteroid . Patient pregnant lactating . Patients w/ screening/baseline total white blood cell count &lt; 4000/mm3 ; platelet count &lt; 100,000/mm3 ; fast triglyceride &gt; 400 mg/dl ( &gt; 4.6 mmol/L ) ; fast total cholesterol &gt; 300 mg/dl ( &gt; 7.8 mmol/L ) ; fast HDLcholesterol &lt; 30 mg/dl ; fast LDLcholesterol &gt; 200 mg/dl . Patient unlikely comply w/ visit . Patient w/ form substance abuse , psychiatric disorder condition , investigator 's opinion , may invalidate communication . Expected tacrolimus instituted 5 day postoperatively . Patients w/ cytotoxic PRA value &gt; 10 % time preenrollment . Patients w/ Graves disease , unless previously treat w/ radioiodine ablative therapy . History idiopathic thrombocytopenic purpura ( ITP ) thrombotic thrombocytopenic purpura ( TTP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Transplants</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>HLA Antigens</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Bone Marrow</keyword>
</DOC>